Identification of biomarkers that can be used for the prognostic evaluation of NSCLC patients is important. The aim of this study was to evaluate the potential prognostic value of XRCC1, ERCC1, ERCC2, and TP53 SNPs in completely resected NSCLC patients.One hundred and thirty patients, who had been surgically treated for NSCLC between 2000 and 2012, were included in this study. Analysis of SNPs from peripheral blood cells was performed by PCR. XRCC1 Arg399Gln, ERCC1 Asn118Asn, ERCC2 Lys751Gln, andTP53 Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters and survival. Kaplan–Meier method and Cox regression analysis were used.In the univariate analysis for disease-free survival (DFS), postoperative stage (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.26–0.96; p=0.03), ERCC2 genotype (HR 2.47, 95% CI 1.28–4.78; p=0.007), and PET-CT staging (HR 0.27, 95%CI 0.14–0.52; p<0.001) were significant parameters. Adjuvant chemotherapy, age, and the other SNPs were not significant. In the multivariate analysis, post-operative stage (HR 0.40, 95% CI 0.20–0.81; p=0.01), ERCC2 genotype (HR 2.66, 95% CI 1.35–5.27; p=0.005), PET-CT staging (HR 0.24, 95% CI 0.12–0.47; p<0.001) retained their significance. Median DFS was 56.5months (95% CI 24.6–88.4) for the ERCC2 mutant (TT) and heterozygote (GT) genotypes, and 28.3months (95% CI 20.8–35.8) for the ERCC2 normal (GG) genotype (p =0.005).In addition to stage and PET-CT staging, ERCC2 genotype independently predicted DFS in resected NSCLC patients. Future prospective studies are needed for the further evaluation of potential prognostic SNPs in resected NSCLC.